Show simple item record

dc.contributor.authorKerns, SL
dc.contributor.authorFachal, L
dc.contributor.authorDorling, L
dc.contributor.authorBarnett, GC
dc.contributor.authorBaran, A
dc.contributor.authorPeterson, DR
dc.contributor.authorHollenberg, M
dc.contributor.authorHao, K
dc.contributor.authorNarzo, AD
dc.contributor.authorAhsen, ME
dc.contributor.authorPandey, G
dc.contributor.authorBentzen, SM
dc.contributor.authorJanelsins, M
dc.contributor.authorElliott, RM
dc.contributor.authorPharoah, PDP
dc.contributor.authorBurnet, NG
dc.contributor.authorDearnaley, DP
dc.contributor.authorGulliford, SL
dc.contributor.authorHall, E
dc.contributor.authorSydes, MR
dc.contributor.authorAguado-Barrera, ME
dc.contributor.authorGómez-Caamaño, A
dc.contributor.authorCarballo, AM
dc.contributor.authorPeleteiro, P
dc.contributor.authorLobato-Busto, R
dc.contributor.authorStock, R
dc.contributor.authorStone, NN
dc.contributor.authorOstrer, H
dc.contributor.authorUsmani, N
dc.contributor.authorSinghal, S
dc.contributor.authorTsuji, H
dc.contributor.authorImai, T
dc.contributor.authorSaito, S
dc.contributor.authorEeles, R
dc.contributor.authorDeRuyck, K
dc.contributor.authorParliament, M
dc.contributor.authorDunning, AM
dc.contributor.authorVega, A
dc.contributor.authorRosenstein, BS
dc.contributor.authorWest, CML
dc.date.accessioned2019-06-24T08:52:06Z
dc.date.issued2020-02-01
dc.identifier.citationJournal of the National Cancer Institute, 2020, 112 (2), pp. 179 - 190
dc.identifier.issn0027-8874
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3268
dc.identifier.eissn1460-2105
dc.identifier.doi10.1093/jnci/djz075
dc.description.abstractBACKGROUND: A total of 10%-20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction and inform functional mechanistic studies. METHODS: We conducted an individual patient data meta-analysis of six genome-wide association studies (n = 3871) in men of European ancestry who underwent radiotherapy for prostate cancer. Radiotoxicities (increased urinary frequency, decreased urinary stream, hematuria, rectal bleeding) were graded prospectively. We used grouped relative risk models to test associations with approximately 6 million genotyped or imputed variants (time to first grade 2 or higher toxicity event). Variants with two-sided Pmeta less than 5 × 10-8 were considered statistically significant. Bayesian false discovery probability provided an additional measure of confidence. Statistically significant variants were evaluated in three Japanese cohorts (n = 962). All statistical tests were two-sided. RESULTS: Meta-analysis of the European ancestry cohorts identified three genomic signals: single nucleotide polymorphism rs17055178 with rectal bleeding (Pmeta = 6.2 × 10-10), rs10969913 with decreased urinary stream (Pmeta = 2.9 × 10-10), and rs11122573 with hematuria (Pmeta = 1.8 × 10-8). Fine-scale mapping of these three regions was used to identify another independent signal (rs147121532) associated with hematuria (Pconditional = 4.7 × 10-6). Credible causal variants at these four signals lie in gene-regulatory regions, some modulating expression of nearby genes. Previously identified variants showed consistent associations (rs17599026 with increased urinary frequency, rs7720298 with decreased urinary stream, rs1801516 with overall toxicity) in new cohorts. rs10969913 and rs17599026 had similar effects in the photon-treated Japanese cohorts. CONCLUSIONS: This study increases the understanding of the architecture of common genetic variants affecting radiotoxicity, points to novel radio-pathogenic mechanisms, and develops risk models for testing in clinical studies. Further multinational radiogenomics studies in larger cohorts are worthwhile.
dc.formatPrint
dc.format.extent179 - 190
dc.languageeng
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS INC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleRadiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.
dc.typeJournal Article
dcterms.dateAccepted2019-04-29
rioxxterms.versionofrecord10.1093/jnci/djz075
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of the National Cancer Institute
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radiotherapy Physics Modelling
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radiotherapy Physics Modelling
pubs.publication-statusPublished
pubs.volume112
pubs.embargo.termsNot known
icr.researchteamICR-CTSU Urology and Head and Neck Trials Team
icr.researchteamClinical Academic Radiotherapy (Dearnaley)
icr.researchteamOncogenetics
icr.researchteamRadiotherapy Physics Modelling
dc.contributor.icrauthorDearnaley, David
dc.contributor.icrauthorHall, Emma
dc.contributor.icrauthorEeles, Rosalind


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0